Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 27;12:820191. doi: 10.3389/fphar.2021.820191

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Tregnago, Benetton, Da Ros, Borella, Longo, Polato, Francescato, Biffi and Pigazzi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Expression of antiapoptotic proteins of BCL-2 family in pediatric acute myeloid leukemia (AML). (A) Supervised analysis according to BCL-2 expression (left panel) and dot plots (right panel) showing BCL-2, BCL-2 S70, and MCL-1 protein expression of a cohort of 66 AML pediatric patients subcategorized in KMT2A-rearranged AML and non-KMT2A-rearranged AML, analyzed with the reverse-phase protein array method. Quartiles refer to BCL-2 expression. Dot plots show the mean ± SEM. A.U., arbitrary units. (B) Pearson correlation between BCL-2 S70 (X-axis) and BCL-2 (Y-axis) in the upper panel and MCL-1 (X-axis) and BCL-2 (Y-axis) in the lower panel; p < 0.00001. (C) Dose–response curve of growing concentrations of venetoclax in KMT2A-rearranged AML (SHI-1, THP-1, and NOMO-1) and non-KMT2A-rearranged AML (HL-60) cell lines at 72 h after treatment (n = 2).